The selectivity profile of venadaparib on diverse panels covering 88 kinds of enzymes and receptors involved in the cardiovascular, respiratory, and nervous systems was performed at Eurofins Panlabs. Screening was performed using either a radioligand binding assay or an enzymatic assay. Venadaparib was tested at 10 μmol/L in duplicate, and results showing relative inhibition higher than 50% were considered to be significant. Relative inhibition ranging from 25% to 50% was indicative of weak to moderate effects, and results showing a relative inhibition lower than 25% were not considered significant.